Tags: Asceneuron


Top Five Highlights from AAIC 2018

The ADDF looks back at the 2018 Alzheimer's Association International Conference.


Looking Ahead on World Alzheimer's Day

On World Alzheimer’s Day, we celebrate the progress made toward finding effective treatments and look toward the future. 


Asceneuron Awarded Alzheimer’s Drug Discovery Foundation Grant

Asceneuron SA, an emerging leader in small molecule therapeutics targeting tauopathies for Alzheimer's and related neurodegenerative diseases, was awarded a $325,000 grant from the ADDF to support the development of its tau modulators.